Pharmaceutical combinations for the treatment of dispidemia accompanied hypertension

摘要

1. - a synergistic Pharmaceutical composition which comprises a combination of a CoA reductase reductase inhibitor known as antihypertensive rosuvastatin calcium, an inhibitor of calcium channels known as amlodipine besylate and antiplatelet Drugs known C Omo ACETYLSALICYLIC ACID. 2.The pharmaceutical composition according to claim 1, characterized in that it comprises a synergistic Composition of Rosuvastatin calcium equivalent of Rosuvastatin 5 mg amlodipine besylate, equivalent to 5 mg amlodipine and ACETYLSALICYLIC ACID 75 mg in a single Unit Oral dose (3 Capsules or tablets).The pharmaceutical composition according to claim 1 and 2, wherein the composition comprises a synergistic rosuvastatin calcium equivalent to 10 mg of Rosuvastatin, amlodipine besylate, equivalent to 5 mg amlodipine and ACETYLSALICYLIC ACID in a single 75 mg Ability of oral dose (4 Capsules or tablets).The pharmaceutical composition according to claim 1, 2 and 3, wherein the combination of Ingredients offers a product with improved Properties, which requires less amount of at least one ingredient and produces an effect sinu00e9rgico.5.The pharmaceutical composition according to claim 1, 2, 3 and 4, wherein the combination of Ingredients improves significantly the levels of Serum cholesterol, blood pressure, reduces the risk of cardiovascular and cerebrovascular Ischemic Events. A reduced risk of adverse events.